The data reported so far for Regeneron Pharmaceuticals Inc.'s evinacumab at the European Atherosclerosis Society (EAS) Congress in Innsbruck, Austria, this week, are from just four homozygous familial hypercholestrolemia (HoFH) patients but they show that evinacumab reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55% (mean reduction; range 25-90%) from baseline at week four when used on top of current therapy.
Regeneron Shows Proof Of Concept For Novel Cholesterol Drug
An investigational hypolipemic product from Regeneron Pharmaceuticals with a novel mechanism of action appears to have great promise when used in addition to current therapies in familial hypercholesterolemia patients, suggest early data from a small study, but many questions remain.
More from Clinical Trials
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.